Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Description of Pharmacogenetics for Patients with Hepatitis C Virus in the Kingdom of Saudi Arabia: A Single Center Perspective

Speaker(s)

Althemery A1, Alturaiki A2, Alanazi RH2, Almotairi NH2, AL Ammari M3, Alghamdi H3, AlThiab K3
1Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia, 2King Abdulaziz Medical City - National Guard Health Affairs, Riyadh, Saudi Arabia, 3King Abdulaziz Medical City - NGHA, Riyadh, Saudi Arabia

Presentation Documents

OBJECTIVES: Over 71 million people are living with hepatitis C virus (HCV) globally. HCV is an RNA virus that can be classified into different types of genotypes and can lead to multiple complications, including liver cirrhosis, hepatocellular carcinoma, and death. HCV treatments are effective but highly dependent on the HCV genotype and subtype. There are few studies describing the HCV genotype in the Middle East, in particular, Saudi Arabia. This study aims to describe the genotypes of patients with HCV living in Saudi Arabia and their associated treatments.

METHODS: The study was conducted at National Guard Hospital in Riyadh. All adults (18 years and older) diagnosed with HCV who started direct‐acting antiviral agents were identified from the pharmacy records. The relevant clinical factors, including patients’ characteristics, comorbid conditions, treatments, and HCV genotypes, were collected. The baseline viral counts were collected and converted into log algorithm values. The sample size was determined using G*Power analysis software, while all analyses were conducted using R: A language and environment for statistical computing.

RESULTS: A total of 387 patients with HCV were identified, out of which 28.42% were genotype 1, 65.8% were genotype 4, and 5.78% had mixed genotype 1&4. The majority of those patients were elderly (M = 61.4 SD = 0.8). The majority of patients received sofosbuvir (294 patients), ledipasvir )200), ribavirin (190), and paritaprevir (93).

CONCLUSION: It was shown that HCV genotype 4 was predominant in Saudi Arabia, unlike findings in the United States and Northern Europe, where genotype 1 predominates. Future studies are needed to evaluate the effectiveness of direct‐acting antiviral agents with their targeted genotypes.

Code

EPH1

Topic

Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Electronic Medical & Health Records, Reproducibility & Replicability

Disease

Biologics and Biosimilars, Infectious Disease (non-vaccine)